The Claim

In HIV-infected adults on suppressive antiretroviral therapy, daily administration of rosuvastatin (10 mg) for 48 weeks reduces the proportion of tissue factor-positive patrolling monocytes (CD14DimCD16+) by 41.6% compared to placebo, indicating a direct causal effect on monocyte procoagulant activation.

Source: Rosuvastatin reduces vascular inflammation and T cell and monocyte activation in HIV-infected subjects on antiretroviral therapy

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
70score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults with HIV who are on effective antiretroviral treatment, taking 10 mg of rosuvastatin daily for 48 weeks lowers the percentage of a specific type of monocyte that expresses tissue factor by 41.6% compared to a placebo.

See the scientific wording

In HIV-infected adults on suppressive antiretroviral therapy, daily rosuvastatin (10 mg) for 48 weeks reduces the proportion of tissue factor-positive patrolling monocytes (CD14DimCD16+) by 41.6% compared to placebo, indicating a direct causal effect on monocyte procoagulant activation.

Why this might work

Rosuvastatin blocks a key enzyme in cholesterol production, which reduces molecules needed to activate certain signaling proteins inside immune cells. Without these molecules, the signaling proteins cannot turn on inflammation genes, so the immune cells stop producing a protein that triggers blood clotting. This directly reduces the number of clot-promoting immune cells in the bloodstream.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Rosuvastatin reduces vascular inflammation and T cell and monocyte activation in HIV-infected subjects on antiretroviral therapy

    In people with HIV who are on effective treatment, taking a daily rosuvastatin pill for 48 weeks cut down a specific type of immune cell that triggers blood clotting by over 40%, compared to those who took a dummy pill. This shows the drug directly helps reduce this harmful cell activity.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.